Given the robust expression of PD-L1 in EBV-associated NPC and the immunogenic nature of the disease, combining IC with PD-1 blockade may further enhance treatment outcomes by priming the tumor microenvironment for immune-mediated cytotoxicity (19). The gene discussed is CD274; the disease is neoplasm.